Last reviewed · How we verify
Induction Cycles A4-5
Induction Cycles A4-5 is a chemotherapy regimen designed to induce remission in pediatric leukemia patients through sequential administration of multiple cytotoxic agents.
Induction Cycles A4-5 is a chemotherapy regimen designed to induce remission in pediatric leukemia patients through sequential administration of multiple cytotoxic agents. Used for Acute lymphoblastic leukemia (ALL) induction therapy in pediatric patients, Acute myeloid leukemia (AML) induction therapy in pediatric patients.
At a glance
| Generic name | Induction Cycles A4-5 |
|---|---|
| Sponsor | Nationwide Children's Hospital |
| Drug class | Multi-agent chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a multi-agent induction chemotherapy protocol used in pediatric acute leukemia treatment. The regimen combines multiple chemotherapeutic drugs administered in a specific sequence to achieve maximal cytotoxic effect against leukemic blasts while attempting to minimize cumulative toxicity. The exact drug composition and dosing schedule follows a standardized protocol developed by Nationwide Children's Hospital for initial disease control.
Approved indications
- Acute lymphoblastic leukemia (ALL) induction therapy in pediatric patients
- Acute myeloid leukemia (AML) induction therapy in pediatric patients
Common side effects
- Myelosuppression
- Infection
- Mucositis
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
Key clinical trials
- Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma (PHASE3)
- Pressure Recording Analytical Method Parameters and Their Relationship With Hypotension in Hypertensive Patients
- The Effects of Repetitive Transcranial Magnetic Stimulation in Obese People With BED (NA)
- Prevention of Chemotherapy-Related Polyneuropathy Via Sensorimotor Exercise Training (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Induction Cycles A4-5 CI brief — competitive landscape report
- Induction Cycles A4-5 updates RSS · CI watch RSS
- Nationwide Children's Hospital portfolio CI